Prescient Therapeutics adds two more experts to Scientific Advisory Board
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary...
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its...
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Summary Prescient Therapeutics (ASX:PTX): We spoke with Steve Yatomi-Clarke, CEO of Prescient Therapeutics, about the exciting new...
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...
(ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.